home / stock / pstv / pstv news

PSTV News and Press, PLUS THERAPEUTICS Inc. From 03/11/24

Stock Information
Company Name: PLUS THERAPEUTICS Inc.
Stock Symbol: PSTV
Market: NYSE
Menu
PSTV PSTV Quote PSTV Short PSTV News PSTV Articles PSTV Message Board
Get PSTV Alerts

News, Short Squeeze, Breakout and More Instantly...
PSTV - Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

A total of 18 patients have been dosed in the trial to date Company anticipates moving into Cohort 6 in Q2 2024 following standard safety review AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”),...
PSTV - Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript

2024-03-05 19:07:07 ET Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Conference Call March 05, 2024, 05:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Norman LaFrance - CMO Conference Call Participants Justin Walsh ...

PSTV - Plus Therapeutics GAAP EPS of -$4.24 misses by $3.07

2024-03-05 16:09:44 ET More on Plus Therapeutics Plus sees an additional $6.9M in grant revenue in 2024 Seeking Alpha’s Quant Rating on Plus Therapeutics Historical earnings data for Plus Therapeutics Financial information for Plus Therapeutics ...

PSTV - Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Began enrollment of the 5 th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium ( 186 Re) obisbemeda for leptomeningeal metastases (LM) Reached agreement to expand ReSPECT-GBM Phase 2 trial and add new sites ...
PSTV - Expected US Company Earnings on Tuesday, March 5th, 2024

Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...

PSTV - Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024

AUSTIN, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today annou...

PSTV - Plus sees an additional $6.9M in grant revenue in 2024

2023-12-18 07:21:32 ET More on Plus Therapeutics Plus Therapeutics climbs on FDA orphan drug tag for radiotherapy Seeking Alpha’s Quant Rating on Plus Therapeutics Historical earnings data for Plus Therapeutics Financial information for Plus Therapeuti...
PSTV - Plus Updates Financial and Cash Guidance for 2024

Plus Receives $3.3M in grant revenue in Q4 2023 Forecasts additional $6.9M of grant revenue for 2024 Enters into debt restructuring deal with Pershing Capital to reduce 2024 cash burn by $3.7M AUSTIN, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. ...

PSTV - Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses

AUSTIN, Texas, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today...

PSTV - Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe

AUSTIN, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced th...
Previous 10 Next 10